Outcome of Board meeting
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.3 pts less than Nifty Microcap 250 and 2.3 pts less than its Medical Equipment & Supplies peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Prevest Denpro's board, at its meeting on May 27, 2025, approved the audited financial results for the quarter and full year ended March 31, 2025. Standalone Total Income for FY25 rose to Rs. 6,717.76 lakhs from about Rs. 6,301.30 lakhs in FY24, a growth of roughly 6-7%. Standalone Net Profit grew to Rs. 1,820.13 lakhs (from Rs. 1,612.37 lakhs), up about 13%, while consolidated Net Profit came in at Rs. 1,815.52 lakhs (from Rs. 1,613.69 lakhs). The company remains completely debt-free, with cash and equivalents of Rs. 6,046 lakhs standalone and Rs. 6,090 lakhs consolidated. Statutory auditor Mittal & Associates issued an unmodified (clean) opinion on both the standalone and consolidated financial statements.
A clean audit opinion, steady revenue and profit growth, and a debt-free balance sheet with strong cash reserves are positive signals for shareholders, pointing to financial stability and operational consistency.